MP
IBER

Mangrove Partners’s Ibere Pharmaceuticals IBER Stock Holding History

Mangrove Partners’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200,000
Closed -$1.94M – 593
2021
Q4 		$1.94M Hold
200,000
– – 0.12% 343
2021
Q3 		$1.94M Hold
200,000
– – 0.17% 246
2021
Q2 		$1.93M Buy
+200,000
New +$1.95M 0.2% 178

Other funds holding IBER

Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
SCC
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return

Mangrove Partners's IBER Position: Q1 2022 in Review

Mangrove Partners sold out of Ibere Pharmaceuticals (IBER) in Q1 2022, closing a stake of 200,000 shares — an estimated $1.94M sold.

Mangrove Partners first reported a position in IBER in Q2 2021 and held it in 3 quarters. The position peaked at $1.94M in Q4 2021. 48 funds tracked by Wall St. Rank hold IBER as of Q1 2022.

  • Mangrove Partners reported no remaining Ibere Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Mangrove Partners sold 200,000 Ibere Pharmaceuticals shares in Q1 2022, an estimated $1.94M.
  • Mangrove Partners first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 3 quarters.
  • Mangrove Partners's Ibere Pharmaceuticals position peaked at $1.94M in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2022.

Based on Mangrove Partners's 13F filing for Q1 2022, filed 16 May 2022.